Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
About this trial
This is an interventional treatment trial for Androgen Independent Prostate Cancer (AIPC) focused on measuring Calcitriol, DN-101, Androgen Independent Prostate Cancer (AIPC), Prostate Cancer, Non Small Cell Lung Cancer (NSCLC)
Eligibility Criteria
Inclusion Criteria: Prior participation in DN101-002 or DN101-004 studies, where the subject received at least one dose of DN-101 Able and willing to give written informed consent Exclusion Criteria: Disease progression or unacceptable toxicity while previously enrolled in DN101-002 or DN101-004 studies Prior investigational therapy other than DN-101 within 30 days of enrollment Known hypersensitivity to calcitriol Pregnancy (women of childbearing potential only) Greater than 90 days has elapsed from termination of DN101-002 or DN101-004 studies
Sites / Locations
- Alta Bates Comprehensive Cancer Center
- Pacific Hematology Oncology Associates
- Kaiser Permanente Medical Group, Northern California
- Columbia Presbyterian Medical Center
- Piedmont Hematology Oncology Associates
- NW Kaiser Permanente Portland
- Alta Bates Comprehensive Center
- Oregon Health & Science University
- University of Pittsburgh,William Copper Ambulatory Care, Pavillion Hellman Cancer Center
- Tyler Cancer Center
- Northwest Cancer Specialists Vancouver Office
- Tom Baker Cancer Centre
- Cross Cancer Institute, Department of Medicine